GSP Crop Science Ltd
Company mejorly focusing on fungiside and insecticide and related pesticide
- Market Cap ₹ 2,155 Cr.
- Current Price ₹ 463
- High / Low ₹ 470 / 327
- Stock P/E 21.3
- Book Value ₹ 166
- Dividend Yield 0.00 %
- ROCE 19.0 %
- ROE 16.6 %
- Face Value ₹ 10.0
Pros
Cons
- The company has delivered a poor sales growth of 7.09% over past five years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Fertilizers & Agrochemicals Pesticides & Agrochemicals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| 903 | 1,077 | 1,406 | 1,203 | 1,152 | 1,287 | 1,517 | |
| 832 | 949 | 1,273 | 1,125 | 1,028 | 1,137 | 1,332 | |
| Operating Profit | 72 | 129 | 132 | 79 | 124 | 150 | 185 |
| OPM % | 8% | 12% | 9% | 7% | 11% | 12% | 12% |
| 4 | 11 | 13 | 6 | 12 | 14 | 9 | |
| Interest | 25 | 18 | 24 | 37 | 34 | 31 | 37 |
| Depreciation | 18 | 18 | 20 | 21 | 20 | 23 | 30 |
| Profit before tax | 34 | 103 | 101 | 27 | 82 | 110 | 127 |
| Tax % | 36% | 34% | 25% | 21% | 26% | 26% | 26% |
| 21 | 68 | 76 | 22 | 61 | 82 | 95 | |
| EPS in Rs | 72.32 | 229.88 | 256.41 | 77.84 | 235.61 | 21.05 | 21.05 |
| Dividend Payout % | 10% | 4% | 4% | 3% | 4% | 4% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 7% |
| 3 Years: | 8% |
| TTM: | 18% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 8% |
| 3 Years: | 67% |
| TTM: | 25% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 15% |
| 3 Years: | 18% |
| Last Year: | 17% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 29 | 29 | 29 | 27 | 26 | 39 | 47 |
| Reserves | 302 | 366 | 439 | 336 | 344 | 411 | 725 |
| 169 | 139 | 321 | 324 | 235 | 296 | 262 | |
| 242 | 383 | 426 | 444 | 374 | 483 | 513 | |
| Total Liabilities | 742 | 918 | 1,216 | 1,132 | 980 | 1,228 | 1,547 |
| 159 | 161 | 166 | 169 | 177 | 214 | 247 | |
| CWIP | 7 | 9 | 11 | 16 | 51 | 50 | 48 |
| Investments | 2 | 0 | 2 | 3 | 8 | 12 | 16 |
| 573 | 747 | 1,037 | 945 | 745 | 952 | 1,236 | |
| Total Assets | 742 | 918 | 1,216 | 1,132 | 980 | 1,228 | 1,547 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| 80 | 114 | -43 | 104 | 207 | 38 | ||
| -24 | -19 | -42 | -47 | -19 | -80 | ||
| -59 | -50 | 157 | -159 | -178 | 30 | ||
| Net Cash Flow | -3 | 45 | 71 | -102 | 10 | -12 | |
| Free Cash Flow | 64 | 91 | -93 | 70 | 179 | -34 | |
| CFO/OP | 132% | 112% | -22% | 169% | 180% | 45% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor Days | 113 | 99 | 96 | 126 | 103 | 110 | 133 |
| Inventory Days | 119 | 153 | 148 | 155 | 111 | 173 | 136 |
| Days Payable | 113 | 162 | 125 | 156 | 114 | 161 | 147 |
| Cash Conversion Cycle | 120 | 90 | 119 | 125 | 99 | 122 | 121 |
| Working Capital Days | 54 | 51 | 61 | 56 | 39 | 50 | 71 |
| ROCE % | 23% | 19% | 8% | 17% | 21% | 19% |
Documents
Announcements
-
Disclosure Under Regulation 30 (5) Of The SEBI (LODR) Regulations 2015
13h - Board approved FY26 audited results, Rs1 dividend, and appointed Pranav Chitre CFO effective June 1, 2026.
-
Appointment Of Cost Auditor Of The Company For The Financial Year 2026-27
14h - Board approved FY26 audited results, recommended Rs1 dividend, appointed new CFO effective June 1, 2026.
-
Announcement under Regulation 30 (LODR)-Change in Management
14h - Board approved FY26 audited results, recommended Re.1 dividend, and appointed Pranav Chitre CFO from June 1, 2026.
-
Announcement under Regulation 30 (LODR)-Change in Management
14h - Board approved FY26 audited results, Re1 dividend, CFO appointment, and executive re-designation on May 26, 2026.
-
Appointment Of Internal Auditor Of The Company For FY 2026-27
14h - FY26 audited results approved; Re.1 dividend recommended; Pranav Chitre appointed CFO from June 1, 2026.
Concalls
-
Apr 2026Transcript PPT REC
Business Profile[1]
The Company is a research-driven agrochemical company with 40+ years of experience since 1985, focused on the development, manufacturing, and distribution of crop protection products across two verticals — Formulations (finished products) and Technicals (active ingredients).